CClinicalTrials.gg
CompletedNCT05043974VivalDIUpdated Jul 21, 2022

Integrative Study of Physiological Changes Induced by a 5-Day Dry Immersion on 20 Healthy Female Volunteers (DI5-Women)

An interventional study of Dry immersion in Weightlessness and Weightlessness; Adverse Effect, sponsored by Centre National d'Etudes Spatiales. Completed at 1 site in France. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-21.

Sponsored by Centre National d'Etudes Spatiales · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Dry immersion (DI) is a ground-based model of prolonged conditions of simulated microgravity. Dry immersion involves immersing the subject in water covered with an elastic waterproof fabric. As a result, the immersed subject, who is freely suspended in the water mass, remains dry. Within a relatively short duration, the model can faithfully reproduce most physiological effects of actual microgravity, including centralization of body fluids, support unloading, and hypokinesia.

The objective of the study is to evaluate the physiological changes induced by 5 days of dry immersion in the female organism. The main physiological systems will be explored before, during and after the 5 days of immersion through a battery of specific tests and measurements. The results will be analyzed by scientists specializing in each field in order to better understand the dry immersion model, to compare its effects with those of the bedrest model and those of spaceflight. The clinical (adverse effects, comfort of subjects) and operational aspects are also part of the secondary objectives of the study.

Read the detailed description

The space agencies are actively engaged in studying the physiological adaptation to space environment through studies on board the International Space Station (ISS) but also on the ground. Ground-based experiments simulating the effects of weightlessness are used to better understand the mechanisms of physiological adaptation, design and validate the countermeasures. Dry immersion (DI) is a ground-based model of prolonged conditions of simulated microgravity, which has been mainly used in Russia. The past years however, the model has been implemented as well in Europe and expertise in conducting DI studies has been gained in particular in France where a few DI studies have been conducted in the MEDES Space Clinic in Toulouse for CNES (French Space Agency). Dry immersion involves immersing the subject in water covered with an elastic waterproof fabric. As a result, the immersed subject, who is freely suspended in the water mass, remains dry. Within a relatively short duration, the model can faithfully reproduce most physiological effects of actual microgravity, including centralization of body fluids, support unloading, and hypokinesia. Furthermore, physiological changes have been reported in the neuromuscular, skeletal and sensorimotor systems, in fluid electrolyte regulation, in the cardiovascular system, metabolism, blood and immunity, respiration, and thermoregulation. Dry immersion provides a unique opportunity to study the physiological effects of the lack of a supporting structure for the body (a phenomenon called 'supportlessness'). As such, dry immersion is proposed to mimic actual spaceflight in terms of the monotonous environment, posture-motion limitations, hemodynamic changes and hypokinetic effects, support unloading, and decreased proprioceptive input. Immersion studies have so far only been conducted in men and a minority of studies using the bedrest model have included women. Likewise, few studies conducted to date have investigated gender differences in the astronaut population. The small number of female astronauts may be part of the reason why scientific data are lacking to draw valid conclusions about possible gender differences. However, if women currently constitute only about 10% of astronauts, women are and will be more and more represented in crews. Women now constitute 30% of American crews and NASA (US space agency) has announced gender parity for crews on future lunar missions. It is therefore essential to study the physiological changes induced by weightlessness in women, to compare them with those observed in men and to develop efficient countermeasures for preventing them. The main physiological systems will be explored before, during and after the 5 days of immersion through a battery of specific standardized tests and measurements. The objective of the study is to evaluate the physiological changes induced by 5 days of dry immersion in the female organism. The study conditions such as patient recruitment, nutrition, data collection, data management, reporting for adverse events are standardized. The results will be analyzed by scientists specializing in each field in order to better understand the dry immersion model, to compare its effects with those of the bedrest model and those of spaceflight. The clinical (adverse effects, comfort of subjects) and operational aspects are also part of the secondary objectives of the study.

Twenty healthy female subjects will participate in the study. There is no published data on dry immersion with female participation to help calculation the sample size. Moreover, female spaceflight and bedrest data are scarce, and do not provide any insight into inter-individual variability. This prolonged DI protocol in women is conceived as a pilot, descriptive, explorative study, as well as an operational and methodological study. Power-based calculation of the number of subjects is not directly applicable for such explorative studies. However, based on effect sizes obtained with previous DI studies in men, a total of 20 subjects was deemed necessary for this study.

02

Conditions studied

  • Weightlessness
  • Weightlessness; Adverse Effect

Keywords

  • Simulated Microgravity
  • Weightlessness
  • Dry immersion
  • Supportlessness
03

In context

Lead sponsor

Centre National d'Etudes Spatiales is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy female volunteer (see below the description of medical tests and laboratory analysis performed at the selection visit),
  • Age 20 to 40,
  • No overweight nor excessive thinness with BMI (weight Kg/ height m2) between 20 and 26,
  • Height between 158cm and 180 cm,
  • Regular menstrual cycles and cycles lasting between 20 and 35 days,
  • Without oestroprogestative contraception (i.e., oral progestative contraception, IUDs, implants or absence of contraception are allowed),
  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination): in particular, free from any chronic disease or any acute infectious disease or cardiovascular, neurological, ENT (especially orthostatic hypotension and vestibular disorders), orthopaedic or musculoskeletal disorders,
  • Fitness level assessment:

    • if age \< 35 years: 35 ml/min./kg \< VO2max \< 55 ml/min./kg,
    • if age > 35 years: 30 ml/min./kg \< VO2max \< 55 ml/min./kg,
  • Non active smokers,
  • No alcohol, or drug addiction, and no medical treatment (with the exception of the aforementioned accepted means of contraception),
  • Covered by a Health Insurance System,
  • Having signed the informed consent,
  • Free from any engagement during the study.

Exclusion criteria

Exclusion Criteria:

  • Any history or presence of clinically relevant cardiovascular, neurological or ENT (especially orthostatic hypotension and vestibular disorders), any chronic disease; any acute infectious disease, in particular,
  • Symptomatic orthostatic hypotension whatever the decrease in blood pressure,
  • Asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within 3 minutes when changing from the supine to the standing position,
  • Cardiac rhythm disorders,
  • Hypertension,
  • Chronic back pains,
  • Vertebral fracture, scoliosis or herniated disc,
  • Glaucoma,
  • Self-reported hearing problems,
  • History of migraines,
  • History of hiatus hernia or gastro-esophageal reflux,
  • History of thyroid dysfunction, renal stones, diabetes,
  • History of head trauma,
  • Abnormal result for lower limbs echo-doppler,
  • History of genetic muscle and bone diseases of any kind,
  • Past records of thrombophlebitis, family history of thrombosis or positive response in thrombosis screening procedure (anti thrombin III, S-protein, C-protein, factor V Leiden mutation and the mutation 20210 of the prothrombin gene),
  • Women who have stopped breastfeeding within 2 months before the start of the study,
  • Women who have undergone an abortion within 3 months before the start of the study,
  • Irregular menstrual cycles or cycles lasting less than 20 days or more than 35 days,
  • Oestroprogestative contraception,
  • Recent implementation or change in hormonal contraceptive (in the last 6 months),
  • Bone mineral density: T-score ≤ -1.5,
  • Poor tolerance to blood sampling,
  • Having given whole blood (more than 8ml/kg) in a period of 8 weeks or less before the start of the experiment, or having given whole blood more than 3 times in the past year,
  • Significant history of allergy, especially no dermatological allergy,
  • History of food allergy,
  • Significant anomaly detected in the biological analysis,
  • Positive reaction to any of the following tests: HVA IgM (hepatitis A), HBs antigen (hepatitis B), anti-HVC antibodies (hepatitis C), anti-HIV1+2 antibodies,
  • Vegetarian or vegan,
  • Refusal to give permission to contact her general practitioner,
  • Subject who, in the judgment of the investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development,
  • Subject already participating or in the exclusion period of a clinical research,
  • Subject who has received more than 4500 Euros within 12 months for being a research subject,
  • Subject who cannot be contacted in case of emergency,

MRI contraindications

  • History or active claustrophobia,
  • Osteosynthesis material, presence of metallic implants or any other contra-indication for MRI,
  • Allergy to Gadolinium.

Vulnerable persons according to law "Code de la Santé Publique" (L1121-5 to L1121-8) :

  • Pregnant women (urine pregnancy test performed at the selection visit and on the day of arrival in the facility),
  • Women during childbirth and breastfeeding mothers,
  • Persons deprived of their liberty by an administrative or judicial decision,
  • Persons under involuntary psychiatric care,
  • Persons admitted in a health or social establishment for purposes other than research,
  • Minors,
  • Adults subject to legal protection (subject under guardianship or trusteeship) or unable to express their consent.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Dry immersion

    5 days of dry-immersion.

    Other: Dry immersion

Interventions

  • OtherDry immersion

    Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.

06

What researchers measure

Primary outcomes

  1. Change in orthostatic tolerance

    Orthostatic tolerance will be assessed during a Lower Body Negative Pressure test (LBNP test)

    Time frame: At baseline and after five days of dry immersion

  2. Change in peak aerobic power (VO2max test)

    Exercise capacity wil be assessed by graded cycling on sitting ergometer until exhaustion

    Time frame: At baseline and after five days of dry immersion

  3. Change in plasma volume

    Plasma volume (L) will be assessed by the CO-rebreathing method.

    Time frame: At baseline and after five days of dry immersion

  4. Change in fluid shift distribution towards the cephalic region

    The hemodynamic and morphologic consequences of the fluid shift on the cephalic blood vessels (jugular vein, carotid, femoral, intracranial veins) and on the left ventricle will be investigated by ultrasound. The hormones involved in fluid distribution will be assessed in blood and urine samples

    Time frame: At baseline, the first day to quantify the short term effect and the fifth day of dry-immersion to quantify the long term effect of fluid shift

  5. Change in vascular endothelium integrity

    Vascular endothelium integrity will be assessed by blood parameters of vascular and endothelial integrity. Global score of endothelial state will be calculated.

    Time frame: At baseline and during the five days of the dry-immersion period

  6. Change in circadian rhythms of blood pressure

    Continuous 24-h recording of blood pressure will be performed by SOMNOtouch™ NIBP system designed for ambulatory continuous measurements

    Time frame: At baseline and during the five days of the dry-immersion period

  7. Change in lower limb veins functions

    Venous compliance of lower limbs will be assessed by plethysmography.

    Time frame: At baseline, after four days of dry-immersion and after one day of recovery

  8. Change in body fluid compartments by bioelectrical impedance analysis

    Extracellular, intracellular and total body water will be estimated by bioimpedance

    Time frame: Baseline and during five days of dry-immersion

  9. Change in muscle strength

    Muscle strength will be assessed from single leg isometric maximal voluntary contraction on the knee extensors \& flexors, the plantarflexors and dorsiflexors. The Isometric Torque will be measured in Nm. The peak of the three maximal attempts will be recorded for strength measures.

    Time frame: At baseline and after five days of dry-immersion

  10. Change in muscle fatigue

    Muscle fatigability will be assessed during a submaximal isometric knee extension contraction held for 30 seconds at 50% of the baseline MVC value.

    Time frame: At baseline and after five days of dry-immersion

  11. Change in muscle volume at calf level

    Muscle dehydration, eventual atrophy and fatty degeneration will be measured by quantitative Dixon MRI sequences at calf level

    Time frame: At baseline and after five days of dry-immersion

  12. Change in contraction time

    Contraction time will be assessed during a tensiomyographic test in vastus lateralis, Gastrocnemius medialis and Biceps femoris of dominant leg / arm

    Time frame: At baseline and after five days of dry-immersion

  13. Change in bone metabolism

    Bone metabolism in response to immobilization by dry immersion will be assessed by measuring bone biomarkers in blood samples.

    Time frame: At baseline, during and after 5 days of dry-immersion

  14. Changes in cartilage metabolism

    Cartilage metabolism in response to immobilization by dry immersion will be assessed by measuring cartilage biomarkers in blood and urine samples.

    Time frame: At baseline, during and after 5 days of dry-immersion

  15. Change in Resting Metabolic Rate (RMR)

    RMR will be measured by indirect calorimetry technique

    Time frame: At baseline, during and after 5 days of dry-immersion

  16. Change in nitrogen balance

    Nitrogen balance is a measure of nitrogen input minus nitrogen output. Nitrogen intake is calculated with a nutrition software. Protein oxidation measured in the 24-Hour urine collection estimates nitrogen output.

    Time frame: At baseline, during and after 5 days of dry-immersion

  17. Change in Body Composition measured by DEXA

    DEXA is a standard clinical technique to assess body composition

    Time frame: At baseline and at the end of the 5 days of dry-immersion

  18. Change in glucose tolerance (Oral Glucose Tolerance Test)

    Glucose and insulin levels will be measured at baseline (fasting) and 30, 60, 90, and 120 minutes after drinking within 5 min a water solution containing 75 g of glucose.

    Time frame: At baseline and after 3 days of dry-immersion (to be comparable to a previous study on men)

  19. Change in Core temperature

    Measured by electronic ingestible temperature capsules (e-Celsius Performance)

    Time frame: At baseline and during the 5 days of dry immersion

  20. Change in height

    Measured in supine and standing position

    Time frame: At baseline, during and after the 5 days of dry immersion

  21. Change in mid cerebral artery (MCA) blood flow velocity

    Transcranial Doppler measurements

    Time frame: Before and after the 5 days of dry immersion

  22. Change in mood

    Change in mood is assessed using the Profile of Mood States (POMS) questionnaire. (POMS).

    Time frame: At baseline, during and after 5 days of dry-immersion

  23. Change in psychological affects

    PANAS Questionnaire will be used to assess the intensity of positive and negative affective states

    Time frame: At baseline, during and after 5 days of dry-immersion

  24. Change in psychological state: sleep quality

    Pittsburgh Sleep Dairy will be used to assess sleep perceived quality

    Time frame: At baseline, during and after 5 days of dry-immersion

  25. Change in psychological state: mental health

    GHQ-28 Questionnaire will be used to assess psychological well-being and capture distress

    Time frame: At baseline, during and after 5 days of dry-immersion

  26. Change in psychological state: coping strategies

    Brief Cope Questionnaire, designed to measure effective and ineffective ways to cope with a stressful life event, will be used to assess coping strategies

    Time frame: At baseline, during and after 5 days of dry-immersion

  27. Change in cerebral autoregulation

    Transcranial Doppler measurements of mid cerebral artery blood flow velocity will allow to determine cerebral autoregulation

    Time frame: At baseline and after 5 days of dry-immersion

  28. Change in Intra Cranial Pressure (ICP)

    ICP changes will be monitored through OtoAcoustic Emissions (OAE).

    Time frame: At baseline, during and after 5 days of dry-immersion

  29. Change in optic nerve sheath diameter (ONSD) considered as an indirect marker for intracranial pressure (ICP) estimation.

    The optic nerve sheath diameter (ONSD) variations will be measured by echography.

    Time frame: At baseline, during and after 5 days of dry-immersion

  30. Change in the optic nerve fibers thickness.

    Thickness of the optic nerve fibers will be measured by Optical Coherence Tomography (OCT)

    Time frame: At baseline and after five days of dry-immersion

  31. Change in intraocular pressure (IOP)

    IOP measured by applanation

    Time frame: At baseline, during and after five days of dry-immersion

  32. Change in visual acuity

    Far and near visual acuity are tested uncorrected, or if applicable with own correction with digital acuity system.

    Time frame: At baseline and after five days of dry-immersion

  33. Change in visual field

    Visual field measured by standard automated perimetry

    Time frame: At baseline and after five days of dry-immersion

  34. Change in the anatomical characteristics of the eye (optical biometry)

    Optical biometry measured by partial coherence interferometry

    Time frame: At baseline and after five days of dry-immersion

  35. Change in the central corneal thickness

    Central corneal thickness on a single point on the cornea measured by Ultrasonic pachymetry

    Time frame: At baseline and after five days of dry-immersion

  36. Change in the retina by non-mydriatic fundus retinography

    Non-mydriatic fundus retinography allows a fundus photography to be taken and thus a color image of the papilla, retinal vessels and macula.

    Time frame: At baseline and after five days of dry-immersion

  37. Change in the cornea topography

    Cornea topography measured by corneal topography equipment (like Pentacam). The elevation topography according to Scheimpflug principle allows the mapping of the anterior and posterior surface of the cornea.

    Time frame: At baseline and after five days of dry-immersion

  38. Change in cerebral structures and in venous circulation of the brain by MRI

    Visualization of cerebral structures and intracranial venous system will be performed by MRI coupled with injection of gadolinium.

    Time frame: At baseline and after five days of dry-immersion

  39. Change in walking balance

    Walking balance will be assessed by Dynamic Gait Index, specific parameter is: total Score (range 0-24). Higher scores mean a better outcome.

    Time frame: At baseline and after five days of dry-immersion

  40. Change in standing balance

    Standing balance will be assessed by posturography eyes open and eyes closed on a platform covered with 12-cm thick medium density foam.

    Time frame: At baseline and after five days of dry-immersion

  41. Change in motion sickness susceptibility

    Motion Sickness Questionnaire

    Time frame: At baseline and after five days of dry-immersion

  42. Change in coagulation cascade

    Coagulation cascade in response to immobilization by dry immersion will be assessed by measuring coagulation parameters in blood.

    Time frame: At baseline, during and after 5 days of dry immersion

07

Study locations

1 site
  • Medes-Imps
    Toulouse, 31400, France
08

References and documents

Publications

  • Navasiolava NM, Custaud MA, Tomilovskaya ES, Larina IM, Mano T, Gauquelin-Koch G, Gharib C, Kozlovskaya IB. Long-term dry immersion: review and prospects. Eur J Appl Physiol. 2011 Jul;111(7):1235-60. doi: 10.1007/s00421-010-1750-x. Epub 2010 Dec 14. PubMed 21161267 ↗
  • De Abreu S, Amirova L, Murphy R, Wallace R, Twomey L, Gauquelin-Koch G, Raverot V, Larcher F, Custaud MA, Navasiolava N. Multi-System Deconditioning in 3-Day Dry Immersion without Daily Raise. Front Physiol. 2017 Oct 13;8:799. doi: 10.3389/fphys.2017.00799. eCollection 2017. PubMed 29081752 ↗
  • Kermorgant M, Leca F, Nasr N, Custaud MA, Geeraerts T, Czosnyka M, Arvanitis DN, Senard JM, Pavy-Le Traon A. Impacts of Simulated Weightlessness by Dry Immersion on Optic Nerve Sheath Diameter and Cerebral Autoregulation. Front Physiol. 2017 Oct 12;8:780. doi: 10.3389/fphys.2017.00780. eCollection 2017. PubMed 29075198 ↗
  • Linossier MT, Amirova LE, Thomas M, Normand M, Bareille MP, Gauquelin-Koch G, Beck A, Costes-Salon MC, Bonneau C, Gharib C, Custaud MA, Vico L. Effects of short-term dry immersion on bone remodeling markers, insulin and adipokines. PLoS One. 2017 Aug 14;12(8):e0182970. doi: 10.1371/journal.pone.0182970. eCollection 2017. PubMed 28806419 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05043974
Lead sponsor
Centre National d'Etudes Spatiales
Collaborators
European Space Agency
Responsible party
Sponsor
First posted
Sep 14, 2021
Start date
Aug 24, 2021
Primary completion
Dec 8, 2021
Completion
Dec 10, 2021
Last update
Jul 21, 2022

Study contacts

Arnaud BECK, MD
principal investigator · MEDES - IMPS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion